Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.65
61.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Chongqing Zhifei Biological Products Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Revenue
Chongqing Zhifei Biological Products Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥36.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
47%
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥7.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
337%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥2.9B
|
CAGR 3-Years
59%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
Glance View
Chongqing Zhifei Biological Products Co., Ltd., nestled in the fast-paced city of Chongqing, embodies the nexus between innovative biotechnology and practical healthcare solutions. Founded amidst the booming biotech wave, Zhifei has steadily evolved into a substantial player in the vaccine and biopharmaceutical sector. The company’s core operations revolve around the research, development, production, and sales of vaccines and medical diagnostics, ensuring it caters to the surging demand for advanced healthcare solutions both domestically and internationally. Its product line spans from vaccines aimed at combating infectious diseases to diagnostic tools that aid in addressing public health challenges. Moreover, with a robust R&D wing, Zhifei continuously thrives on innovation, channeling significant investments into developing new vaccines that meet the changing needs of global health landscapes. Zhifei’s business model is tightly interwoven with the fabric of healthcare infrastructure, where its profitability hinges not just on product sales but also on strategic collaborations and licenses. Engaging in partnerships with other global pharmaceutical giants and research entities, Zhifei amplifies its market reach and technological prowess. It navigates through the intricacies of regulatory approvals and market distribution with a balanced approach through joint ventures and distribution agreements, which enhance its footprint in regions with burgeoning healthcare needs. Through a lens of sustainable growth, the company marries its entrepreneurial spirit with operational excellence, thus sustaining its ascendancy in the biopharma industry, while contributing to public health improvements worldwide.
See Also
What is Chongqing Zhifei Biological Products Co Ltd's Revenue?
Revenue
36.4B
CNY
Based on the financial report for Sep 30, 2024, Chongqing Zhifei Biological Products Co Ltd's Revenue amounts to 36.4B CNY.
What is Chongqing Zhifei Biological Products Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
47%
Over the last year, the Revenue growth was -27%. The average annual Revenue growth rates for Chongqing Zhifei Biological Products Co Ltd have been 12% over the past three years , 31% over the past five years , and 47% over the past ten years .
You don't have any saved screeners yet
